Abstract
Abrocitinib si selective Janus kinase (JAK) 1 inhibitor that blocks downstream signalling of key cytokines involved in the pathogenesis of atopic dermatitis (AD), such as IL-4, IL-13, IL-22, IL-31 or TSLP. It has been registered based on the resuls of the placebo-controllled phase IIII clinical trials JADE MONO-1, JADE MONO-2 and JADE COMPARE, which showed its high efficacy in terms of alleviating the signs and symptoms of AD; in the JADE DARE trial, the superiority of abrocitinib (at dose of 200 mg) over dupilumab has been demonstrated.
From a clinical point of view, especially the rapid and significant selief of pruritus with abrocitinib treatment, accompanied y an improvement in the patient's quality of life, is prticularly important.